Stratification of High-risk Prostate Cancer into Prognostic Categories: A European Multi-institutional Study
Abstract Background High-risk prostate cancer (PCa) is an extremely heterogeneous disease. A clear definition of prognostic subgroups is mandatory. Objective To develop a pretreatment prognostic model for PCa-specific survival (PCSS) in high-risk PCa based on combinations of unfavorable risk factors...
Gespeichert in:
Veröffentlicht in: | European urology 2015-01, Vol.67 (1), p.157-164 |
---|---|
Hauptverfasser: | , , , , , , , , , , , , , , , , , , |
Format: | Artikel |
Sprache: | eng |
Schlagworte: | |
Online-Zugang: | Volltext |
Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
container_end_page | 164 |
---|---|
container_issue | 1 |
container_start_page | 157 |
container_title | European urology |
container_volume | 67 |
creator | Joniau, Steven Briganti, Alberto Gontero, Paolo Gandaglia, Giorgio Tosco, Lorenzo Fieuws, Steffen Tombal, Bertrand Marchioro, Giansilvio Walz, Jochen Kneitz, Burkhard Bader, Pia Frohneberg, Detlef Tizzani, Alessandro Graefen, Markus van Cangh, Paul Karnes, R. Jeffrey Montorsi, Francesco Van Poppel, Hein Spahn, Martin |
description | Abstract Background High-risk prostate cancer (PCa) is an extremely heterogeneous disease. A clear definition of prognostic subgroups is mandatory. Objective To develop a pretreatment prognostic model for PCa-specific survival (PCSS) in high-risk PCa based on combinations of unfavorable risk factors. Design, setting, and participants We conducted a retrospective multicenter cohort study including 1360 consecutive patients with high-risk PCa treated at eight European high-volume centers. Intervention Retropubic radical prostatectomy with pelvic lymphadenectomy. Outcome measurements and statistical analysis Two Cox multivariable regression models were constructed to predict PCSS as a function of dichotomization of clinical stage (20 ng/ml). The first “extended” model includes all seven possible combinations; the second “simplified” model includes three subgroups: a good prognosis subgroup (one single high-risk factor); an intermediate prognosis subgroup (PSA >20 ng/ml and stage cT3–4); and a poor prognosis subgroup (GS 8–10 in combination with at least one other high-risk factor). The predictive accuracy of the models was summarized and compared. Survival estimates and clinical and pathologic outcomes were compared between the three subgroups. Results and limitations The simplified model yielded an R2 of 33% with a 5-yr area under the curve (AUC) of 0.70 with no significant loss of predictive accuracy compared with the extended model (R2 : 34%; AUC: 0.71). The 5- and 10-yr PCSS rates were 98.7% and 95.4%, 96.5% and 88.3%, 88.8% and 79.7%, for the good, intermediate, and poor prognosis subgroups, respectively ( p = 0.0003). Overall survival, clinical progression-free survival, and histopathologic outcomes significantly worsened in a stepwise fashion from the good to the poor prognosis subgroups. Limitations of the study are the retrospective design and the long study period. Conclusions This study presents an intuitive and easy-to-use stratification of high-risk PCa into three prognostic subgroups. The model is useful for counseling and decision making in the pretreatment setting. |
doi_str_mv | 10.1016/j.eururo.2014.01.020 |
format | Article |
fullrecord | <record><control><sourceid>proquest_cross</sourceid><recordid>TN_cdi_proquest_miscellaneous_1629956565</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><els_id>1_s2_0_S0302283814000712</els_id><sourcerecordid>1629956565</sourcerecordid><originalsourceid>FETCH-LOGICAL-c487t-daf54a5443a329ba3270e83d981a4468850d3740c7d0274267037e448e2f03e73</originalsourceid><addsrcrecordid>eNqFkU9v1DAQxS0EokvpN0AoRy4J4z-JEw5I1apQpCIqLT1brjNZvM3Gi-1U2m_fibZw4IIsjaXR84zf7zH2jkPFgTcfdxXOcY6hEsBVBbwCAS_Yirdalrpu4CVbgQRRila2Z-xNSjsAkHUnX7MzoVTbSNArNm5ytNkP3lENUxGG4tpvf5XRp4fiNoaUbcZibSeHsfBTDktzO1HfO2pn3IboMX0qLosr-swB7VR8n8fsSz-RJs_LVDsWmzz3x7fs1WDHhBfP9zm7-3L1c31d3vz4-m19eVM61epc9naola2VklaK7p6KBmxl37XcKtW0bQ291Aqc7kFoJRoNUiNZQjGARC3P2YfT3EMMv2dM2ex9cjiOdsIwJ8Mb0XV1Q4ek6iR15DVFHMwh-r2NR8PBLJzNzpw4m4WzAW6IMz17_7xhvt9j__fRH7Ak-HwSIPl89BhNch6JYu8jumz64P-34d8BbvQTxTQ-4BHTLsyRuJIXk4QBs1myXqLmimLWXMgnHIWliA</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>1629956565</pqid></control><display><type>article</type><title>Stratification of High-risk Prostate Cancer into Prognostic Categories: A European Multi-institutional Study</title><source>MEDLINE</source><source>Elsevier ScienceDirect Journals Complete</source><creator>Joniau, Steven ; Briganti, Alberto ; Gontero, Paolo ; Gandaglia, Giorgio ; Tosco, Lorenzo ; Fieuws, Steffen ; Tombal, Bertrand ; Marchioro, Giansilvio ; Walz, Jochen ; Kneitz, Burkhard ; Bader, Pia ; Frohneberg, Detlef ; Tizzani, Alessandro ; Graefen, Markus ; van Cangh, Paul ; Karnes, R. Jeffrey ; Montorsi, Francesco ; Van Poppel, Hein ; Spahn, Martin</creator><creatorcontrib>Joniau, Steven ; Briganti, Alberto ; Gontero, Paolo ; Gandaglia, Giorgio ; Tosco, Lorenzo ; Fieuws, Steffen ; Tombal, Bertrand ; Marchioro, Giansilvio ; Walz, Jochen ; Kneitz, Burkhard ; Bader, Pia ; Frohneberg, Detlef ; Tizzani, Alessandro ; Graefen, Markus ; van Cangh, Paul ; Karnes, R. Jeffrey ; Montorsi, Francesco ; Van Poppel, Hein ; Spahn, Martin ; European Multicenter Prostate Cancer Clinical and Translational Research Group (EMPaCT)</creatorcontrib><description>Abstract Background High-risk prostate cancer (PCa) is an extremely heterogeneous disease. A clear definition of prognostic subgroups is mandatory. Objective To develop a pretreatment prognostic model for PCa-specific survival (PCSS) in high-risk PCa based on combinations of unfavorable risk factors. Design, setting, and participants We conducted a retrospective multicenter cohort study including 1360 consecutive patients with high-risk PCa treated at eight European high-volume centers. Intervention Retropubic radical prostatectomy with pelvic lymphadenectomy. Outcome measurements and statistical analysis Two Cox multivariable regression models were constructed to predict PCSS as a function of dichotomization of clinical stage (<cT3 vs cT3–4), Gleason score (GS) (2–7 vs 8–10), and prostate-specific antigen (PSA; ≤20 ng/ml vs >20 ng/ml). The first “extended” model includes all seven possible combinations; the second “simplified” model includes three subgroups: a good prognosis subgroup (one single high-risk factor); an intermediate prognosis subgroup (PSA >20 ng/ml and stage cT3–4); and a poor prognosis subgroup (GS 8–10 in combination with at least one other high-risk factor). The predictive accuracy of the models was summarized and compared. Survival estimates and clinical and pathologic outcomes were compared between the three subgroups. Results and limitations The simplified model yielded an R2 of 33% with a 5-yr area under the curve (AUC) of 0.70 with no significant loss of predictive accuracy compared with the extended model (R2 : 34%; AUC: 0.71). The 5- and 10-yr PCSS rates were 98.7% and 95.4%, 96.5% and 88.3%, 88.8% and 79.7%, for the good, intermediate, and poor prognosis subgroups, respectively ( p = 0.0003). Overall survival, clinical progression-free survival, and histopathologic outcomes significantly worsened in a stepwise fashion from the good to the poor prognosis subgroups. Limitations of the study are the retrospective design and the long study period. Conclusions This study presents an intuitive and easy-to-use stratification of high-risk PCa into three prognostic subgroups. The model is useful for counseling and decision making in the pretreatment setting.</description><identifier>ISSN: 0302-2838</identifier><identifier>EISSN: 1873-7560</identifier><identifier>DOI: 10.1016/j.eururo.2014.01.020</identifier><identifier>PMID: 24486307</identifier><language>eng</language><publisher>Switzerland: Elsevier B.V</publisher><subject>Aged ; Area Under Curve ; Disease-Free Survival ; Europe ; High-risk prostate cancer ; Humans ; Locally advanced prostate cancer ; Male ; Middle Aged ; Neoplasm Grading ; Neoplasm Staging ; Predictive Value of Tests ; Proportional Hazards Models ; Prostate-Specific Antigen - blood ; Prostatic Neoplasms - blood ; Prostatic Neoplasms - classification ; Prostatic Neoplasms - pathology ; Retrospective Studies ; Risk Assessment - methods ; Risk Factors ; Risk groups ; Risk stratification ; Survival Rate ; Urology</subject><ispartof>European urology, 2015-01, Vol.67 (1), p.157-164</ispartof><rights>European Association of Urology</rights><rights>2014 European Association of Urology</rights><rights>Copyright © 2014 European Association of Urology. Published by Elsevier B.V. All rights reserved.</rights><lds50>peer_reviewed</lds50><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c487t-daf54a5443a329ba3270e83d981a4468850d3740c7d0274267037e448e2f03e73</citedby><cites>FETCH-LOGICAL-c487t-daf54a5443a329ba3270e83d981a4468850d3740c7d0274267037e448e2f03e73</cites></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktohtml>$$Uhttps://www.sciencedirect.com/science/article/pii/S0302283814000712$$EHTML$$P50$$Gelsevier$$H</linktohtml><link.rule.ids>314,776,780,3537,27901,27902,65534</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/24486307$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Joniau, Steven</creatorcontrib><creatorcontrib>Briganti, Alberto</creatorcontrib><creatorcontrib>Gontero, Paolo</creatorcontrib><creatorcontrib>Gandaglia, Giorgio</creatorcontrib><creatorcontrib>Tosco, Lorenzo</creatorcontrib><creatorcontrib>Fieuws, Steffen</creatorcontrib><creatorcontrib>Tombal, Bertrand</creatorcontrib><creatorcontrib>Marchioro, Giansilvio</creatorcontrib><creatorcontrib>Walz, Jochen</creatorcontrib><creatorcontrib>Kneitz, Burkhard</creatorcontrib><creatorcontrib>Bader, Pia</creatorcontrib><creatorcontrib>Frohneberg, Detlef</creatorcontrib><creatorcontrib>Tizzani, Alessandro</creatorcontrib><creatorcontrib>Graefen, Markus</creatorcontrib><creatorcontrib>van Cangh, Paul</creatorcontrib><creatorcontrib>Karnes, R. Jeffrey</creatorcontrib><creatorcontrib>Montorsi, Francesco</creatorcontrib><creatorcontrib>Van Poppel, Hein</creatorcontrib><creatorcontrib>Spahn, Martin</creatorcontrib><creatorcontrib>European Multicenter Prostate Cancer Clinical and Translational Research Group (EMPaCT)</creatorcontrib><title>Stratification of High-risk Prostate Cancer into Prognostic Categories: A European Multi-institutional Study</title><title>European urology</title><addtitle>Eur Urol</addtitle><description>Abstract Background High-risk prostate cancer (PCa) is an extremely heterogeneous disease. A clear definition of prognostic subgroups is mandatory. Objective To develop a pretreatment prognostic model for PCa-specific survival (PCSS) in high-risk PCa based on combinations of unfavorable risk factors. Design, setting, and participants We conducted a retrospective multicenter cohort study including 1360 consecutive patients with high-risk PCa treated at eight European high-volume centers. Intervention Retropubic radical prostatectomy with pelvic lymphadenectomy. Outcome measurements and statistical analysis Two Cox multivariable regression models were constructed to predict PCSS as a function of dichotomization of clinical stage (<cT3 vs cT3–4), Gleason score (GS) (2–7 vs 8–10), and prostate-specific antigen (PSA; ≤20 ng/ml vs >20 ng/ml). The first “extended” model includes all seven possible combinations; the second “simplified” model includes three subgroups: a good prognosis subgroup (one single high-risk factor); an intermediate prognosis subgroup (PSA >20 ng/ml and stage cT3–4); and a poor prognosis subgroup (GS 8–10 in combination with at least one other high-risk factor). The predictive accuracy of the models was summarized and compared. Survival estimates and clinical and pathologic outcomes were compared between the three subgroups. Results and limitations The simplified model yielded an R2 of 33% with a 5-yr area under the curve (AUC) of 0.70 with no significant loss of predictive accuracy compared with the extended model (R2 : 34%; AUC: 0.71). The 5- and 10-yr PCSS rates were 98.7% and 95.4%, 96.5% and 88.3%, 88.8% and 79.7%, for the good, intermediate, and poor prognosis subgroups, respectively ( p = 0.0003). Overall survival, clinical progression-free survival, and histopathologic outcomes significantly worsened in a stepwise fashion from the good to the poor prognosis subgroups. Limitations of the study are the retrospective design and the long study period. Conclusions This study presents an intuitive and easy-to-use stratification of high-risk PCa into three prognostic subgroups. The model is useful for counseling and decision making in the pretreatment setting.</description><subject>Aged</subject><subject>Area Under Curve</subject><subject>Disease-Free Survival</subject><subject>Europe</subject><subject>High-risk prostate cancer</subject><subject>Humans</subject><subject>Locally advanced prostate cancer</subject><subject>Male</subject><subject>Middle Aged</subject><subject>Neoplasm Grading</subject><subject>Neoplasm Staging</subject><subject>Predictive Value of Tests</subject><subject>Proportional Hazards Models</subject><subject>Prostate-Specific Antigen - blood</subject><subject>Prostatic Neoplasms - blood</subject><subject>Prostatic Neoplasms - classification</subject><subject>Prostatic Neoplasms - pathology</subject><subject>Retrospective Studies</subject><subject>Risk Assessment - methods</subject><subject>Risk Factors</subject><subject>Risk groups</subject><subject>Risk stratification</subject><subject>Survival Rate</subject><subject>Urology</subject><issn>0302-2838</issn><issn>1873-7560</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2015</creationdate><recordtype>article</recordtype><sourceid>EIF</sourceid><recordid>eNqFkU9v1DAQxS0EokvpN0AoRy4J4z-JEw5I1apQpCIqLT1brjNZvM3Gi-1U2m_fibZw4IIsjaXR84zf7zH2jkPFgTcfdxXOcY6hEsBVBbwCAS_Yirdalrpu4CVbgQRRila2Z-xNSjsAkHUnX7MzoVTbSNArNm5ytNkP3lENUxGG4tpvf5XRp4fiNoaUbcZibSeHsfBTDktzO1HfO2pn3IboMX0qLosr-swB7VR8n8fsSz-RJs_LVDsWmzz3x7fs1WDHhBfP9zm7-3L1c31d3vz4-m19eVM61epc9naola2VklaK7p6KBmxl37XcKtW0bQ291Aqc7kFoJRoNUiNZQjGARC3P2YfT3EMMv2dM2ex9cjiOdsIwJ8Mb0XV1Q4ek6iR15DVFHMwh-r2NR8PBLJzNzpw4m4WzAW6IMz17_7xhvt9j__fRH7Ak-HwSIPl89BhNch6JYu8jumz64P-34d8BbvQTxTQ-4BHTLsyRuJIXk4QBs1myXqLmimLWXMgnHIWliA</recordid><startdate>20150101</startdate><enddate>20150101</enddate><creator>Joniau, Steven</creator><creator>Briganti, Alberto</creator><creator>Gontero, Paolo</creator><creator>Gandaglia, Giorgio</creator><creator>Tosco, Lorenzo</creator><creator>Fieuws, Steffen</creator><creator>Tombal, Bertrand</creator><creator>Marchioro, Giansilvio</creator><creator>Walz, Jochen</creator><creator>Kneitz, Burkhard</creator><creator>Bader, Pia</creator><creator>Frohneberg, Detlef</creator><creator>Tizzani, Alessandro</creator><creator>Graefen, Markus</creator><creator>van Cangh, Paul</creator><creator>Karnes, R. Jeffrey</creator><creator>Montorsi, Francesco</creator><creator>Van Poppel, Hein</creator><creator>Spahn, Martin</creator><general>Elsevier B.V</general><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>7X8</scope></search><sort><creationdate>20150101</creationdate><title>Stratification of High-risk Prostate Cancer into Prognostic Categories: A European Multi-institutional Study</title><author>Joniau, Steven ; Briganti, Alberto ; Gontero, Paolo ; Gandaglia, Giorgio ; Tosco, Lorenzo ; Fieuws, Steffen ; Tombal, Bertrand ; Marchioro, Giansilvio ; Walz, Jochen ; Kneitz, Burkhard ; Bader, Pia ; Frohneberg, Detlef ; Tizzani, Alessandro ; Graefen, Markus ; van Cangh, Paul ; Karnes, R. Jeffrey ; Montorsi, Francesco ; Van Poppel, Hein ; Spahn, Martin</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c487t-daf54a5443a329ba3270e83d981a4468850d3740c7d0274267037e448e2f03e73</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2015</creationdate><topic>Aged</topic><topic>Area Under Curve</topic><topic>Disease-Free Survival</topic><topic>Europe</topic><topic>High-risk prostate cancer</topic><topic>Humans</topic><topic>Locally advanced prostate cancer</topic><topic>Male</topic><topic>Middle Aged</topic><topic>Neoplasm Grading</topic><topic>Neoplasm Staging</topic><topic>Predictive Value of Tests</topic><topic>Proportional Hazards Models</topic><topic>Prostate-Specific Antigen - blood</topic><topic>Prostatic Neoplasms - blood</topic><topic>Prostatic Neoplasms - classification</topic><topic>Prostatic Neoplasms - pathology</topic><topic>Retrospective Studies</topic><topic>Risk Assessment - methods</topic><topic>Risk Factors</topic><topic>Risk groups</topic><topic>Risk stratification</topic><topic>Survival Rate</topic><topic>Urology</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Joniau, Steven</creatorcontrib><creatorcontrib>Briganti, Alberto</creatorcontrib><creatorcontrib>Gontero, Paolo</creatorcontrib><creatorcontrib>Gandaglia, Giorgio</creatorcontrib><creatorcontrib>Tosco, Lorenzo</creatorcontrib><creatorcontrib>Fieuws, Steffen</creatorcontrib><creatorcontrib>Tombal, Bertrand</creatorcontrib><creatorcontrib>Marchioro, Giansilvio</creatorcontrib><creatorcontrib>Walz, Jochen</creatorcontrib><creatorcontrib>Kneitz, Burkhard</creatorcontrib><creatorcontrib>Bader, Pia</creatorcontrib><creatorcontrib>Frohneberg, Detlef</creatorcontrib><creatorcontrib>Tizzani, Alessandro</creatorcontrib><creatorcontrib>Graefen, Markus</creatorcontrib><creatorcontrib>van Cangh, Paul</creatorcontrib><creatorcontrib>Karnes, R. Jeffrey</creatorcontrib><creatorcontrib>Montorsi, Francesco</creatorcontrib><creatorcontrib>Van Poppel, Hein</creatorcontrib><creatorcontrib>Spahn, Martin</creatorcontrib><creatorcontrib>European Multicenter Prostate Cancer Clinical and Translational Research Group (EMPaCT)</creatorcontrib><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>MEDLINE - Academic</collection><jtitle>European urology</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Joniau, Steven</au><au>Briganti, Alberto</au><au>Gontero, Paolo</au><au>Gandaglia, Giorgio</au><au>Tosco, Lorenzo</au><au>Fieuws, Steffen</au><au>Tombal, Bertrand</au><au>Marchioro, Giansilvio</au><au>Walz, Jochen</au><au>Kneitz, Burkhard</au><au>Bader, Pia</au><au>Frohneberg, Detlef</au><au>Tizzani, Alessandro</au><au>Graefen, Markus</au><au>van Cangh, Paul</au><au>Karnes, R. Jeffrey</au><au>Montorsi, Francesco</au><au>Van Poppel, Hein</au><au>Spahn, Martin</au><aucorp>European Multicenter Prostate Cancer Clinical and Translational Research Group (EMPaCT)</aucorp><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Stratification of High-risk Prostate Cancer into Prognostic Categories: A European Multi-institutional Study</atitle><jtitle>European urology</jtitle><addtitle>Eur Urol</addtitle><date>2015-01-01</date><risdate>2015</risdate><volume>67</volume><issue>1</issue><spage>157</spage><epage>164</epage><pages>157-164</pages><issn>0302-2838</issn><eissn>1873-7560</eissn><abstract>Abstract Background High-risk prostate cancer (PCa) is an extremely heterogeneous disease. A clear definition of prognostic subgroups is mandatory. Objective To develop a pretreatment prognostic model for PCa-specific survival (PCSS) in high-risk PCa based on combinations of unfavorable risk factors. Design, setting, and participants We conducted a retrospective multicenter cohort study including 1360 consecutive patients with high-risk PCa treated at eight European high-volume centers. Intervention Retropubic radical prostatectomy with pelvic lymphadenectomy. Outcome measurements and statistical analysis Two Cox multivariable regression models were constructed to predict PCSS as a function of dichotomization of clinical stage (<cT3 vs cT3–4), Gleason score (GS) (2–7 vs 8–10), and prostate-specific antigen (PSA; ≤20 ng/ml vs >20 ng/ml). The first “extended” model includes all seven possible combinations; the second “simplified” model includes three subgroups: a good prognosis subgroup (one single high-risk factor); an intermediate prognosis subgroup (PSA >20 ng/ml and stage cT3–4); and a poor prognosis subgroup (GS 8–10 in combination with at least one other high-risk factor). The predictive accuracy of the models was summarized and compared. Survival estimates and clinical and pathologic outcomes were compared between the three subgroups. Results and limitations The simplified model yielded an R2 of 33% with a 5-yr area under the curve (AUC) of 0.70 with no significant loss of predictive accuracy compared with the extended model (R2 : 34%; AUC: 0.71). The 5- and 10-yr PCSS rates were 98.7% and 95.4%, 96.5% and 88.3%, 88.8% and 79.7%, for the good, intermediate, and poor prognosis subgroups, respectively ( p = 0.0003). Overall survival, clinical progression-free survival, and histopathologic outcomes significantly worsened in a stepwise fashion from the good to the poor prognosis subgroups. Limitations of the study are the retrospective design and the long study period. Conclusions This study presents an intuitive and easy-to-use stratification of high-risk PCa into three prognostic subgroups. The model is useful for counseling and decision making in the pretreatment setting.</abstract><cop>Switzerland</cop><pub>Elsevier B.V</pub><pmid>24486307</pmid><doi>10.1016/j.eururo.2014.01.020</doi><tpages>8</tpages></addata></record> |
fulltext | fulltext |
identifier | ISSN: 0302-2838 |
ispartof | European urology, 2015-01, Vol.67 (1), p.157-164 |
issn | 0302-2838 1873-7560 |
language | eng |
recordid | cdi_proquest_miscellaneous_1629956565 |
source | MEDLINE; Elsevier ScienceDirect Journals Complete |
subjects | Aged Area Under Curve Disease-Free Survival Europe High-risk prostate cancer Humans Locally advanced prostate cancer Male Middle Aged Neoplasm Grading Neoplasm Staging Predictive Value of Tests Proportional Hazards Models Prostate-Specific Antigen - blood Prostatic Neoplasms - blood Prostatic Neoplasms - classification Prostatic Neoplasms - pathology Retrospective Studies Risk Assessment - methods Risk Factors Risk groups Risk stratification Survival Rate Urology |
title | Stratification of High-risk Prostate Cancer into Prognostic Categories: A European Multi-institutional Study |
url | https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-02-20T08%3A30%3A41IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_cross&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Stratification%20of%20High-risk%20Prostate%20Cancer%20into%20Prognostic%20Categories:%20A%20European%20Multi-institutional%20Study&rft.jtitle=European%20urology&rft.au=Joniau,%20Steven&rft.aucorp=European%20Multicenter%20Prostate%20Cancer%20Clinical%20and%20Translational%20Research%20Group%20(EMPaCT)&rft.date=2015-01-01&rft.volume=67&rft.issue=1&rft.spage=157&rft.epage=164&rft.pages=157-164&rft.issn=0302-2838&rft.eissn=1873-7560&rft_id=info:doi/10.1016/j.eururo.2014.01.020&rft_dat=%3Cproquest_cross%3E1629956565%3C/proquest_cross%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=1629956565&rft_id=info:pmid/24486307&rft_els_id=1_s2_0_S0302283814000712&rfr_iscdi=true |